

# CITATION REPORT

List of articles citing

**Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary**

**DOI: 10.1016/j.ejpb.2020.08.005**

**European Journal of Pharmaceutics and Biopharmaceutics, 2020, 155, 55-68.**

**Source:** <https://exaly.com/paper-pdf/75818497/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
28	The ADME Encyclopedia. <b>2021</b> , 1-6		
27	On Absorption Modeling and Food Effect Prediction of Rivaroxaban, a BCS II Drug Orally Administered as an Immediate-Release Tablet. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	6
26	Lost in modelling and simulation?. <i>ADMET and DMPK</i> , <b>2021</b> , 9, 75-109	1.3	9
25	Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	2
24	In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 1373-1385	6.2	0
23	Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies. <i>Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 110, 3896-3906	3.9	5
22	Biorelevant dissolution testing and physiologically based absorption modeling to predict in vivo performance of supersaturating drug delivery systems. <i>International Journal of Pharmaceutics</i> , <b>2021</b> , 607, 120958	6.5	3
21	Six years of progress in the oral biopharmaceutics area - A summary from the IMI OrBiTo project. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2020</b> , 152, 236-247	5.7	12
20	Mechanistic Models for USP2 Dissolution Apparatus, Including Fluid Hydrodynamics and Sedimentation. <i>Journal of Pharmaceutical Sciences</i> , <b>2021</b> ,	3.9	3
19	Predicting Pharmacokinetics of Multisource Acyclovir Oral Products Through Physiologically Based Biopharmaceutics Modeling. <i>Journal of Pharmaceutical Sciences</i> , <b>2021</b> ,	3.9	0
18	On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state. <i>European Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 168, 106034	5.1	2
17	An IQ Consortium Perspective on Connecting Dissolution Methods to In Vivo Performance: Analysis of an Industrial Database and Case Studies to Propose a Workflow.. <i>AAPS Journal</i> , <b>2022</b> , 24, 49	3.7	0
16	Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective.. <i>European Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 106100	5.1	3
15	Physiologically Based Absorption Modelling to Explore the Formulation and Gastric pH Changes on the Pharmacokinetics of Acalabrutinib.. <i>Pharmaceutical Research</i> , <b>2022</b> , 1	4.5	0
14	Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. <i>Pharmaceutics</i> , <b>2022</b> , 14, 1010	6.4	1
13	The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives.. <i>Pharmaceutical Research</i> , <b>2022</b> ,	4.5	1
12	Physiologically Based Biopharmaceutics Modeling (PBBM). <b>2022</b> , 966-971		

11	Applications of bio-predictive dissolution tools for the development of solid oral dosage forms: current industry experience. <i>Drug Development and Industrial Pharmacy</i> , 1-19	3.6	0
10	Efficient drug development of oseltamivir capsules based on process control, bioequivalence and PBPK modeling. <i>Drug Development and Industrial Pharmacy</i> , 1-36	3.6	0
9	A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling. <i>Pharmaceutics</i> , <b>2022</b> , 14, 1474	6.4	1
8	Physiologically Based Biopharmaceutics Model for Selumetinib Food Effect Investigation and Capsule Dissolution Safe Space [Part I: Adults.		1
7	In Vitro-In Vivo Relationship in Mini-Scale Enabling Formulations of Corallopyronin A. <b>2022</b> , 14, 1657		0
6	Modelling and simulation approaches to support formulation optimization, clinical development and regulatory assessment of the topically applied formulations [Nimesulide solution gel case study. <b>2022</b> , 178, 140-149		
5	Predicting the Pharmacokinetics of Orally Administered Drugs across BCS Classes 1-4 by Virtual Bioequivalence Model.		0
4	Physiologically based biopharmaceutics modeling of regional and colon absorption in humans. <b>2023</b> , 186, 144-159		0
3	Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective. <b>2023</b> , 24,		0
2	Acalabrutinib Maleate Tablets: The Physiologically Based Biopharmaceutics Model behind the Drug Product Dissolution Specification. <b>2023</b> , 20, 2181-2193		0
1	Conjunction of semi-mechanistic in vitro-in vivo modeling and population pharmacokinetics as a tool for virtual bioequivalence analysis - a case study for a BCS class II drug. <b>2023</b> , 186, 132-143		0